Lupin: Complex generics and specialty medicines drive growth

LUPIN Lupin: Complex generics and specialty medicines drive growth Lupin Limited (NSE: LUPIN) is strengthening its presence across respiratory therapies, complex generics and specialty pharmaceuticals, with opportunities in both domestic and international markets. **Why it matters:** Complex generics and specialty products can offer better growth opportunities than conventional formulations. However, regulatory approvals, pricing pressure in the US market and competition from generic manufacturers can affect profitability. **My view:** Lupin's long-term performance depends on sustaining its respiratory franchise while expanding its specialty and complex-generic portfolio. Product launches need to translate into meaningful market share, revenue growth and improved margins. **What to watch:** US formulation sales, respiratory product performance, new product approvals, domestic growth, research and development spending and operating margins. **Stance:** The specialty and complex-generics opportunity is encouraging, but consistent execution, regulatory progress and sustainable profitability remain key to the investment case. Disclosure: I am a SEBI Registered Research Analyst. This content is for educational purposes and is not a recommendation to buy or sell any security.